ITI Pharma and Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹195 Cr

Expense Ratio

0.47%

ISIN

INF00XX01BO9

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

11 Nov 2021

About this fund

ITI Pharma and Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by ITI Mutual Fund. This fund has been in existence for 2 years, 10 months and 9 days, having been launched on 11-Nov-21.
As of 19-Sep-24, it has a Net Asset Value (NAV) of ₹17.79, Assets Under Management (AUM) of 194.84 Crores, and an expense ratio of 0.47%.

ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 22.33% since inception.
The fund's asset allocation comprises around 98.89% in equities, 0.00% in debts, and 1.11% in cash & cash equivalents.
You can start investing in ITI Pharma and Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+54.04%

+52.48% (Cat Avg.)

Since Inception

+22.33%

— (Cat Avg.)

Portfolio Summaryas of 31st August 2024

Equity	₹192.67 Cr	98.89%
Others	₹2.17 Cr	1.11%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹31.03 Cr	15.92%
Lupin Ltd	Equity	₹13.73 Cr	7.04%
Apollo Hospitals Enterprise Ltd	Equity	₹10.81 Cr	5.55%
Suven Pharmaceuticals Ltd	Equity	₹10.32 Cr	5.30%
Cipla Ltd	Equity	₹10.14 Cr	5.21%
Aurobindo Pharma Ltd	Equity	₹8.78 Cr	4.51%
Divi's Laboratories Ltd	Equity	₹8.52 Cr	4.37%
Dr Reddy's Laboratories Ltd	Equity	₹7.77 Cr	3.99%
Zydus Lifesciences Ltd	Equity	₹7.3 Cr	3.75%
Laurus Labs Ltd	Equity	₹5.4 Cr	2.77%
Syngene International Ltd	Equity	₹5.23 Cr	2.68%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹5.13 Cr	2.63%
Alkem Laboratories Ltd	Equity	₹4.03 Cr	2.07%
Orchid Pharma Ltd	Equity	₹3.95 Cr	2.03%
Alembic Pharmaceuticals Ltd	Equity	₹3.95 Cr	2.03%
Piramal Pharma Ltd	Equity	₹3.92 Cr	2.01%
Ipca Laboratories Ltd	Equity	₹3.84 Cr	1.97%
Archean Chemical Industries Ltd	Equity	₹3.56 Cr	1.83%
FDC Ltd	Equity	₹3.5 Cr	1.79%
HealthCare Global Enterprises Ltd	Equity	₹3.08 Cr	1.58%
Mankind Pharma Ltd	Equity	₹3 Cr	1.54%
Ajanta Pharma Ltd	Equity	₹2.96 Cr	1.52%
Caplin Point Laboratories Ltd	Equity	₹2.81 Cr	1.44%
Vijaya Diagnostic Centre Ltd	Equity	₹2.74 Cr	1.41%
Biocon Ltd	Equity	₹2.52 Cr	1.30%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹2.52 Cr	1.29%
Abbott India Ltd	Equity	₹2.21 Cr	1.13%
Fortis Healthcare Ltd	Equity	₹2.19 Cr	1.13%
Net Receivables / (Payables)	Cash - Collateral	₹2.17 Cr	1.11%
Shilpa Medicare Ltd	Equity	₹2.08 Cr	1.07%
Rainbow Childrens Medicare Ltd	Equity	₹2.04 Cr	1.05%
Strides Pharma Science Ltd	Equity	₹1.98 Cr	1.02%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹1.94 Cr	1.00%
Wockhardt Ltd	Equity	₹1.91 Cr	0.98%
Sumitomo Chemical India Ltd Ordinary Shares	Equity	₹1.91 Cr	0.98%
Emcure Pharmaceuticals Ltd	Equity	₹1.9 Cr	0.98%
Supriya Lifescience Ltd	Equity	₹1.88 Cr	0.97%
Sanofi India Ltd	Equity	₹1.33 Cr	0.68%
Sanofi Consumer He	Equity	₹0.74 Cr	0.38%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹186.47 Cr	95.70%
Basic Materials	₹5.47 Cr	2.81%

Risk & Performance Ratios

Fund Managers

Dhimant Shah

Since December 2022

Rohan Korde

Since November 2021

Additional Scheme Detailsas of 31st August 2024

ISIN

INF00XX01BO9

Expense Ratio

0.47%

Exit Load

1.00%

Fund Size

₹195 Cr

Age

11 Nov 2021

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

Nifty Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
Holding the units: No tax is applicable as long as you continue to hold the units.

Dividend Taxation:

Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹17.49 Cr	53.5%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹862.61 Cr	52.3%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹862.61 Cr	50.2%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹37.00 Cr	50.2%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹194.84 Cr	54.0%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹194.84 Cr	51.1%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2758.76 Cr	50.9%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2758.76 Cr	48.6%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹798.61 Cr	48.5%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹19.93 Cr	49.1%

About the AMC

ITI Mutual Fund

022-66214999

https://www.itimf.com/

Total AUM

₹8,744 Cr

Address

Mumbai, 400013

Other Funds by ITI Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
ITI Focused Equity Fund Direct Growth Very High Risk	0.4%	1.0%	₹498.18 Cr	47.0%
ITI Liquid Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹63.23 Cr	7.1%
ITI Ultra Short Duration Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹149.23 Cr	7.5%
ITI Multi Cap Fund Direct Growth Very High Risk	0.5%	1.0%	₹1393.09 Cr	47.3%
ITI Value Fund Direct Growth Very High Risk	0.5%	1.0%	₹295.38 Cr	44.4%
ITI Conservative Hybrid Fund Direct Growth Moderate Risk	0.2%	0.0%	₹14.80 Cr	8.9%
ITI Dynamic Bond Fund Direct Growth Moderate Risk	0.1%	0.0%	₹36.11 Cr	9.9%
ITI Balanced Advantage Fund Direct Growth Very High Risk	0.6%	1.0%	₹384.05 Cr	25.9%
ITI Small Cap Fund Direct Growth Very High Risk	0.3%	1.0%	₹2355.47 Cr	61.3%
ITI Large Cap Fund Direct Growth Very High Risk	0.5%	1.0%	₹360.61 Cr	35.4%
ITI Banking & PSU Debt Fund Direct Growth Moderate Risk	0.1%	0.0%	₹29.48 Cr	8.2%
ITI Banking and Financial Services Fund Direct Growth Very High Risk	0.4%	1.0%	₹265.73 Cr	19.7%
ITI Arbitrage Fund Direct Growth Low Risk	0.2%	0.0%	₹41.15 Cr	8.1%
ITI Overnight Fund Direct Growth Low Risk	0.1%	0.0%	₹113.49 Cr	6.6%
ITI Mid Cap Fund Direct Growth Very High Risk	0.4%	1.0%	₹1133.77 Cr	61.0%
ITI Long Term Equity Fund Direct Growth Very High Risk	0.5%	0.0%	₹398.29 Cr	56.8%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹194.84 Cr	54.0%
ITI Flexi Cap Fund Direct Growth Very High Risk	0.5%	1.0%	₹1228.13 Cr	50.4%

Risk Level

Your principal amount will be at Very High Risk

Still got questions?
We're here to help.

What is the current NAV of ITI Pharma and Healthcare Fund Direct Growth?

The NAV of ITI Pharma and Healthcare Fund Direct Growth, as of 19-Sep-2024, is ₹17.79.

What is the portfolio composition of ITI Pharma and Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 98.89% in equities, 0.00% in bonds, and 1.11% in cash and cash equivalents.

Who manages the ITI Pharma and Healthcare Fund Direct Growth?

The fund managers responsible for ITI Pharma and Healthcare Fund Direct Growth are:-

Dhimant Shah
Rohan Korde

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

©2021-2022 Dezerv. All Rights Reserved

Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.